熱門資訊> 正文
Ligand通过收购Xoma Royalty恢复对花旗的收购
2026-07-22 03:35
- XOMA Royalty Corporation Depositary Shs Repr 1/1000th 8.375% Cum Conv Perp Red Pfd Rg Shs Series B(XOMAO) 0
- 強生(JNJ) 0
- 羅氏(ADR)(RHHBY) 0
- Citi has resumed its coverage of Ligand Pharmaceuticals (LGND) with a buy rating saying that its acquisition of XOMA Royalty adds a significant number of late-stage assets as well as a steady royalty stream.
- The acquisition, with an equity value of $739M, closed earlier in July.
- The bank has a price target of $387 (~32% return based on July 20 close).
- Analyst Yigal Nochomovitz noted that Ligand could significantly benefit from a contingent value right related to Johnson & Johnson's (JNJ) Tremfya (guselkumab) once ongoing litigation is resolved.
- He added that Ligand will also gain from Xoma's key commercial drivers, Roche (RHHBY) unit Genentech's Vabysmo (faricimab), Day One Biopharmaceuticals' Ojemda (tovorafenib), and Zevra Therapeutics (ZVRA) Miplyffa (arimoclomol).
More on Ligand Pharmaceuticals
- Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator
- Ligand Pharmaceuticals: The Bull Case Is A Biotech ARM, The Bear Case Is Just Another Royalty Trust
- Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript
- Ligand Pharmaceuticals prices $625M convertible debt offering
- Ligand prices proposed $550M convertible senior notes offering
推薦文章
存儲芯片「超級周期」 遠未結束？閃迪低點累計反彈逾70%！下一輪行情該如何部署？
華盛早報 | 英特爾CPU擬10月上旬漲價10%！小米澎程「掀桌子」降價鎖單破萬！中國央行連續22個月增持黃金；江波龍今日港股上市
蘋果新CEO特努斯的首場大考：售價2000美元的摺疊版iPhone
華爾街頭部分析師看好這3只股票的長期投資價值
資金覆盤 | 北水撈底小米超13億港元！搶籌中際旭創超3億港元
華盛早報 | 3600億元！8家中央金融企業獲財政部增資；小米今夜發佈全新摺疊屏+澎程新車；美股周一休市一日
一周財經日曆 | 事關加息！美國8月CPI、PPI重磅來襲，蘋果秋季發佈會倒計時：摺疊屏iPhone終登場
電力將成AI賽道下一個賣鏟人？馬斯克、黃仁勛齊發聲：亟需更多電力投資！美股還有哪些電力概念股？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
